Shanghai Pharmaceuticals (02607.HK) announced its interim results with a net profit attributable to shareholders of approximately 4.459 billion yuan, a year-on-year increase of 51.56%.

The Wise Finance APP reported that Shanghai Pharmaceuticals (02607.HK) announced its mid-term performance for 2025, with operating income of approximately 141.593 billion yuan, a year-on-year increase of 1.56%; the net profit attributable to shareholders of the listed company is approximately 4.459 billion yuan, a year-on-year increase of 51.56%; basic earnings per share is 1.2 yuan.